Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial

Courtney D. DiNardo, Andre C. Schuh, Eytan M. Stein, Pau Montesinos, Andrew H. Wei, Stéphane de Botton, Amer M. Zeidan, Amir T. Fathi, Hagop M. Kantarjian, John M. Bennett, Mark G. Frattini, Patricia Martin‐Regueira, Frederik Lersch, Jing Gong, Maroof Hasan, Paresh Vyas, Hartmut Döhner